Compare GraniteShares 2x Long COIN Daily ETF (CONL) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GraniteShares 2x Long COIN Daily ETF vs DexCom, Inc. — how do they compare? GraniteShares 2x Long COIN Daily ETF trades at $4.87 (market cap $510.01M), while DexCom, Inc. trades at $84.97 (market cap $31.86B). The key difference: DexCom, Inc. is far larger — about 62.5× GraniteShares 2x Long COIN Daily ETF's market cap, and DexCom, Inc. is trading nearer its 52-week high, GraniteShares 2x Long COIN Daily ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GraniteShares 2x Long COIN Daily ETF for 15 Days and DexCom, Inc. for 62 Days on average.
| CONL | DXCM | |
|---|---|---|
Market Cap | $510.01M | $31.86B |
Volume | 21,041,836 | 3,607,070 |
Sector | Leveraged / Inverse | Health |
52-Week High | $48.58 | $92.34 |
52-Week Low | $3.93 | $54.84 |
Typical Hold Time | 15 Days | 62 Days |
Enterprise Value | — | $31.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CONL shares declined 7.76% to $5.23, reflecting significant bearish technical momentum with moving averages signaling strong selling pressure. The ETF faces headwinds from underlying asset volatility, with recent news highlighting substantial losses in the leveraged product structure. Technical indicators show oversold conditions with RSI at 24.76, suggesting potential for near-term bounce despite the dominant downtrend.
The outlook remains challenging given the leveraged ETF's inherent volatility and recent performance struggles. While oversold technicals may provide short-term relief, the product's structure exposes investors to amplified losses during market declines. Risk management is critical given the 2x leverage and concentrated exposure to cryptocurrency-related equities.
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About GraniteShares 2x Long COIN Daily ETF
CONL is a leveraged ETF that seeks to provide two times (2x) the daily performance of Coinbase Global (COIN) stock. It is designed for investors seeking magnified short-term exposure to the price movements of Coinbase.
Read more on CONL →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
